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In the past ten years, our understanding of the importance of bile acids has
expanded from fat absorption and glucose/lipid/energy homeostasis into potential
therapeutic targets for amelioration of chronic cholestatic liver diseases. The discovery
of important bile acid signaling mechanisms, as well as their role in metabolism,
has increased the interest in bile acid/bile acid receptor research development. Bile
acid levels and speciation are dysregulated during liver injury/damage resulting in
cytotoxicity, inflammation, and fibrosis. An increasing focus to target bile acid receptors,
responsible for bile acid synthesis and circulation, such as Farnesoid X receptor and
apical sodium-dependent bile acid transporter to reduce bile acid synthesis have
resulted in clinical trials for treatment of previously untreatable chronic liver diseases
such as non-alcoholic steatohepatitis and primary sclerosing cholangitis. This review
focuses on current bile acid receptor mediators and their effects on parenchymal and
non-parenchymal cells. Attention will also be brought to the gut/liver axis during chronic
liver damage and its treatment with bile acid receptor modulators. Overall, these studies
lend evidence to the importance of bile acids and their receptors on liver disease
establishment and progression.
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INTRODUCTION
Focal studies of hepatic secretion led to the critical analysis and understanding of bile and its
circulation connecting the liver and intestine (1). Bile acids (BAs) are heterogenous compounds
whose chemical and amphipathic properties result from the enzymatic breakdown of insoluble
cholesterol (2). Since their isolation from bile, the field of BA chemistry has provided intensive
study of their complex chemical nature and the physiological effects of their dynamic composition
in circulating bile (2–5).
Hepatic BA build up leads to inflammation, necrosis, and apoptosis of various liver cells which
then affects BA synthesis and transport perpetuating BA-induced damage (2, 3). Due to the
extensive knowledge and research concerning hepatic BA formation and secretion, it is natural
to assume BAs contribute to chronic liver damage. The increased synthesis of BAs in combination
with interrupted BA signaling can lead to adverse effects in patients of chronic liver diseases. It is
estimated that 1.5 billion people worldwide suffer from chronic liver diseases whose complications,
cirrhosis and liver cancer, result in 2 million deaths globally (6). Chronic liver diseases have
an increased burden in the health care system due to the frequent hospital readmissions,
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accompanying hepatic decompensation, and risk for infection as
liver damage progresses (6). Many chronic liver diseases, such as
primary sclerosing cholangitis (PSC) and non-alcoholic fatty liver
disease (NAFLD), have minimal treatment options requiring
liver transplantation as the only permanent remedy (6, 7).
Various therapeutics have been FDA-approved for clinical
trials aiming to improve liver function and relieve adverse effects
of disrupted BA signaling. This article serves as a brief review of
BA signaling and function in various chronic liver diseases and
their regulation of the gut microbiome.
CIRCULATION, MODIFICATION, AND
FUNCTION OF BILE ACIDS
Bile Acid Synthesis and Transport
The catabolism of cholesterol into BAs in the parenchyma is
tightly regulated by over 17 enzymes, preferentially expressed
in the liver, that are involved in the synthesis and alteration of
BAs into bile salts (8, 9). Impairment of these mechanisms can
result in cholestasis, liver damage, impaired lipid metabolism,
and other maladies (3, 5, 8). Modifications and conjugations of
BAs affect their solubility, hydrophobicity, and receptor binding
affinity (8, 10). BA synthesis and conjugations are summarized in
Figure 1 (reprinted with permission from Molinaro et al. Trends
Endocrinol Metab).
Bile acids are secreted into the bile canaliculi by hepatocytes,
draining to the bile ducts located in the portal triad.
Cholangiocytes are the epithelial cells lining the bile ducts
and assist in BA modification and circulation by cholehepatic
shunting, the process in which BAs are reabsorbed from the
bile and returned to hepatocytes (11–14). The intrahepatic bile
duct system allows BAs to flow into the intestinal lumen through
the common hepatic duct in response to food ingestion to
assist in emulsification, metabolism and absorption of dietary
lipids and fat-soluble vitamins (A, D, E, and K). Alternatively,
BAs are deposited in the gallbladder for storage and prevention
of cholesterol-crystallization and gallstone formation (10, 15).
Approximately 95% of BAs are reabsorbed in the distal ileum
by the apical sodium-dependent bile acid transporter (ASBT;
alternatively known as ileal bile acid transporter, IBAT) and
delivered to the liver through the portal system via enterohepatic
or portal circulation (16–18). The gut microbiome is capable
of deconjugating primary bile acids and converting them to
secondary bile acids prior to absorption or fecal excretion
which affects gut microbiome community, BA pool, and liver
health (8, 19, 20).
Abbreviations: ALKP/ALP, Alkaline phosphatase; ASBT, apical sodium bile acid
transporter; AST, aspartate aminotransferase; Bas, bile acids; FXR, Farnesoid X
receptor; CA, cholic acid; CCA, cholangiocarcinoma; CDCA, chenodeoxycholic
acid; DCA, deoxycholic acid; HCC, hepatocellular carcinoma; IBABP, ileal bile
acid binding protein; IBD, irritable bowel disease; IBAT, ileal bile acid transporter;
LCA, lithocholic acid; LDL, low density lipoprotein; MDR2, multidrug resistance
cassette 2; MDR3, multidrug resistance cassette 3; NAFLD, non-alcoholic fatty
liver disease; NASH, non-alcoholic steatohepatitis; OCA, Obeticholic acid; OSTα-
β, organic solute transporter α-β; PBC, primary biliary cholangitis; PSC, primary
sclerosing cholangitis; TBA, total bile acid; TGR5, Takeda G protein coupled
receptor 5; UDCA, Ursodeoxycholic acid.
Aside from their important roles in digestion, BAs can
behave as signaling molecules in carbohydrate and lipid
metabolism, energy expenditure, and hepatic disease (20–22).
BAs and activation of their downstream targets including
G-protein-coupled bile acid receptor (TGR5), transforming
growth factor-α (TGF-α) and sphingosine-1-phosphate
receptor-2 (S1PR2) stimulate cholangiocyte proliferation
and contribute to the progression of cholangiocarcinoma
[CCA, in vivo and in vitro (21–25)]. Alternatively, Farnesoid X
Receptor (FXR) is down regulated in hepatocellular carcinoma
(HCC) (26). It has been shown that FXR via increased
CYP450 epoxygenase activity suppress NF-κB signaling
thereby reducing hepatic inflammation (27, 28). Further
exploration into the anti-inflammatory role of FXR and
assessment of BA direct or indirect targets may provide
understanding of chronic cholestatic disease establishment
and progression.
Intrahepatic and Extrahepatic Bile Acid
Modification
The catabolism of cholesterol results in the formation of
the primary BAs, cholic acid (CA) or chenodeoxycholic acid
(CDCA), through the major (classical) pathway or the minor
(alternative/acidic) pathway, respectively (29). Cholehepatic
shunting alters the BA pool via biliary ASBT transport,
multidrug resistance cassette 3 (MDR3, human; multidrug
resistance cassette 2, mice), and organic solute transporter
α-β (OSTα-β) BA secretion into the peribiliary plexus prior
to reaching the hepatic sinusoids (30). Ileal bile acid binding
protein (IBABP) is expressed in large cholangiocytes to
sequester BAs preventing biliary cytotoxicity (30, 31). CA
and CDCA/Ursodeoxycholic acid (UDCA) are converted
to deoxycholic acid (DCA) and lithocholic acid (LCA),
respectively, via 7α/β-dihydroxylation by various species of
the commensal gut microbiota in the gastrointestinal tract
(32). Human secondary BAs (DCA and LCA) are capable of
being circulated back to the liver via enterohepatic circulation
leading to an increased hepatic levels of damaging hydrophobic
BAs (32).
DYSREGULATION OF BILE ACIDS IN
CHRONIC LIVER DISEASES
PSC and PBC
PSC and Primary Biliary Cholangitis (PBC) are rare cholestatic
liver diseases that affect the biliary system. PSC is an
idiopathic disease with cholestasis, inflammation and eventual
fibrosis resulting from strictures of intra- and extrahepatic
bile ducts (33). PSC is one of the most common causes
for liver transplantation (LT) (33). Due to its heterogenous
and spontaneous progression, effective medical therapies have
not yet been developed (33). Fat-soluble vitamin deficiency
can occur in PSC patients as a result of decreased bile
flow and secretion. It has also been shown that PSC has a
positive correlation with ulcerative colitis (UC), a form of
inflammatory bowel disease (IBD). PSC/IBD patients display
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FIGURE 1 | Human and mouse bile acid synthesis and conjugation. Cholesterol catabolism results in the creation of primary bile acids (BAs) through either the
classical pathway, accomplished by Cytochrome P450 7A1 (CYP7A1), or the alternative/acidic pathway, conducted by Cytochrome P450 27A1 (CYP27A1). Alteration
by various cytochrome P450 family of enzymes allows for the creation of cholic acid (CA) and chenodeoxycholic acid (CDCA). Primary BAs can become conjugated to
glycine or taurine prior to secretion to the biliary ductules. Deconjugation and reconjugation occurs in the distal ileum through bacterial intervention creating secondary
BAs: lithocholic acid (LCA) or deoxycholic acid (DCA). Mice have additional primary BAs: Ursodeoxycholic acid (UDCA) and α- and β-muricholic acid. The murine
specific primary BAs created by cytochrome P450 2C70 (CYP2C70) can also be conjugated to glycine or taurine prior to secretion into bile duct and alteration by gut
microbiota into secondary BAs. Figure reprinted with permission from Molinaro et al. Trends Endocrinol Metab.
altered BA fecal excretion and decreased gut microbiome
diversity compared to healthy or IBD patient controls (34).
Patients with PSC have decreased expression of hepatic FXR,
TGR5, and S1PR2 (35). The multidrug resistance cassette
2 knock-out mouse (MDR2−/−) is a mouse model utilized
to mimic the PSC phenotype including increased cholestasis,
intrahepatic bile duct mass and hepatic inflammation due to
hepatic BA build up (36, 37). This murine model has been
useful for identifying effects of potential therapeutics, such as
UDCA. Meng et al. reported that UDCA treatment in Mdr2−/−
mice reduced serum TBA, elevated hepatic expression of BA
transporters, and reduced hepatic inflammation and collagen
deposition (36).
PBC is a chronic auto-immune disease, predominantly
affecting middle-aged women, that results in biliary ductopenia
and cholestasis. Li et al. reported elevated serum levels
of total BAs (TBA) and FGF19 in cirrhotic PBC patients
compared to healthy controls and non-cirrhotic PBC patients
(38). Similarly, Trottier et al. demonstrated elevated BAs
in serum samples from both PBC and PSC compared to
healthy controls (39). Ursodeoxycholic acid (UDCA), an
epimer of CDCA, was the first FDA-approved treatment
for PBC. Despite increased bile flow, lower liver enzyme
levels, and decreased serum BA levels, one in three PBC
patients will have a limited or no response to treatment,
strengthening the need for effective therapeutic intervention of
PBC progression (33, 40–45).
NAFLD
NAFL and non-alcoholic steatohepatitis (NASH) are two of the
most common hepatic diseases worldwide due to an increase
of sedentary lifestyle and consumption of a high-fat/high-
cholesterol diet (46, 47). Its prevalence has demonstrated positive
correlation with an increasing number of obese and type II
diabetic patients (46). Currently, there are no approved therapies
for the treatment of NAFL and NASH aside from a change of diet
and exercise for gradual weight loss.
BA signaling is disrupted in NAFL and NASH patients
yielding great interest in the search for exogenous methods
of BA regulation (48, 49). Mouzaki et al. uncovered greater
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fecal BA secretion and increased primary to secondary BA ratio
in NASH patients compared to healthy controls (49). Ferslew
et al. found elevated serum BAs in NASH patients, compared
to healthy controls, with an increase of taurine- and glycine-
conjugated BAs (48). Benedict and Zhang proposed that FXR
suppression of hepatic inflammation may ameliorate NAFLD
progression (50).
HCC and CCA
HCC is currently the third leading cause of cancer deaths
worldwide. HCC affects parenchymal cells in the liver, which
make up to 70% of the liver tissue. HCC develops in chronic liver
disease or cirrhotic liver patients and is usually detected through
various imaging methods prior to diagnosis. Patients with HCC
can be asymptomatic or present with a range of symptoms
including cirrhosis-related pain. The underlying chronic liver
injury, and difficulty in diagnosis, both contribute to HCCs
high mortality. CCA is a rare but devastating cancer with
poor prognosis. Patients present with jaundice, pruritus (intense
itch) and acholic (pale) stool due to reduced bile and bilirubin
excretion. Due to the intimate relationship between hepatocytes,
cholangiocytes and BAs it is important to investigate BA signaling
in the establishment and progression of HCC and CCA.
Demonstrating a shift in the BA pool during cancer
development, Changbumrung et al. reported elevated ratios
for trihydroxy to dihydroxy BAs and for glycine-conjugated
to taurine-conjugated BAs in patients with HCC and CCA
compared to healthy patients (51). Luo et al. demonstrated a
similar trend with elevated glycine-conjugated BAs in hepatic
injury patients, ranging from hepatitis B viral infection to
cirrhosis, compared to healthy controls suggesting taurine-
conjugated BAs as a potential sensitive biomarker for liver
injury (52). This increase in BA pool size is due to reduced
inhibition of BA synthesis. FXR activation has been indicated
to have anti-cancer properties, with decreased expression in
progressing human HCC lesions, since its downstream effects
include inhibition of BA synthesis and cell proliferation
(26, 53). Guo et al. reported decreased FXR expression in
HCC tumor lesions, indicating a hindering role in HCC
development and progression (26). Wolfe et al. found a
decrease of FXR expression in HCC tumor lesions, compared
to normal liver tissue, with increasing tumor development
stage (53). Similarly, Liu et al. reported decreased small
heterodimer partner (SHP) and FXR expression in human
HCC compared to paired healthy control (54). Erice et al.
demonstrated FXR expression in CCA samples negatively
correlates with advanced cancer progression and lymph node
invasion. In contrast to FXR, TGR5 expression is elevated in
CCA tumors compared to controls (25). This discovery is likely
due to cholangiocyte requirement of TGR5 for BA-induced
proliferation and anti-apoptosis signaling (55, 56). Additional
BA receptors, such as S1PR2, have been found to have elevated
expression in human CCA tumors, as shown by Liu et al.
(57). Taken together these studies indicate that altered BAs
may serve to enhance HCC and CCA progression during
disease development.
CURRENT BILE ACID-RELATED
THERAPIES OF CHRONIC LIVER
DISEASES
Bile Acid Therapies
The use of synthetic or naturally occurring BAs to reduce
gallstone formation, aid in lipid absorption following gastric
surgeries, and assist in reduction of cholestasis has increased
in recent years. UDCA is a hydrophilic BA conjugated
to undergo enterohepatic circulation or deconjugated and
converted into LCA by the gut microbiome and excreted
into feces. UDCA was the first FDA-approved therapy for
PBC patients exhibiting altered serum liver enzyme levels
(41). UDCA has been a staple therapy due to its ability
to prevent gallstone formation, increasing bicarbonate
secretion to prevent acidification of bile, and positive
side effect profile as compared to treatment with CDCA
(18, 41, 58). In many PBC patients, long-term UDCA
treatment when administered at early stage of disease
increases survival rate, lowers liver enzyme serum levels,
and improves liver histology (41, 43, 59, 60). Regardless of its
beneficial effects, 30–40% of PBC patients do not respond to
UDCA treatment.
UDCA treatment can improve liver histology and
serum ALT/ASP levels in PSC patients, however, data
supporting any long-term efficacy or long-term survival are
lacking (61). Moreover, UDCA prescribed at high doses
increased medical complications and mortality in PSC
patients (61–64). PSC patients treated with norUDCA,
a side chain shortened homolog of UDCA, exhibited
reduced ALP serum levels compared to placebo in a dose-
dependent manner, however norUDCA’s effects on PSC
progression, long-term survival, and mortality have not been
investigated (65).
Bile Acid Receptor/Transporter Agonists
and Antagonists
Obeticholic acid (OCA, Ocaliva) is an FDA-approved, synthetic
derivative of CDCA and is a high affinity ligand for the nuclear
bile acid receptor, FXR (40). FXR is a nuclear BA receptor that
when expressed is capable of reducing BA synthesis, increasing
expression of BA transporters and modulating lipoprotein
metabolism (66). OCA has been studied as a potential therapeutic
drug in the treatment of various chronic liver diseases (40, 44).
Following Phase II and Phase III clinical trials, it has been
suggested that OCA treatment can be delivered in conjunction
with UDCA in PBC, or as a monotherapy in patients who do not
tolerate UDCA, respectively (67, 68). Adverse events including
pruritus occurred in nearly all patients and was observed to
occur in a dose dependent manner (67, 68). The beneficial
effects of OCA as a monotherapy are currently being investigated
in various clinical trials (7, 67, 69). The use of OCA has
promising effects on improving liver enzyme levels, lowering
plasma bilirubin and IgM levels, and has recently been shown
to improve or stabilize liver fibrosis and biliary injury in PBC
patients with cirrhosis (68, 69). Despite promising outcomes in
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PBC patients, long-term effects of OCA on disease progression
and patient survival are still being investigated.
In the Farnesoid X Receptor Ligand Obeticholic Acid in
NASH Treatment (FLINT) clinical trial, NASH patients treated
with OCA presented with improved fibrosis scores, elevated
low-density lipoprotein (LDL) and increased average weight loss
compared to placebo control (46, 70). NASHpatients treated with
OCA also had increased ALP levels compared to placebo control
(46). The effects of OCA on insulin resistance and the observed
improvement of lipid absorption were not sustained following
termination of OCA treatment (46). Further investigation into
the short-term and long-term effects of OCA on liver function
and injury are warranted and are actively being explored
in the Randomized Global Phase III Study to Evaluate the
Impact on NASH with Fibrosis of Obeticholic Acid Treatment
(REGENERATE) clinical trial assessing FXR activation in the
treatment of NASH (71). Translational Research and Evolving
Alcoholic hepatitis Treatment (TREAT) consortium conducted
phase II clinical trial utilizing OCA on patients with moderately
severe alcoholic hepatitis (AH) that was completed in 2018,
however currently no data is available on this study (72). The
Phase 3 Study of Obeticholic Acid in Patients with Primary Biliary
Cirrhosis (POISE) double-blind, placebo controlled clinical trial
has been one of the few to publish results demonstrating OCA’s
long-term safety and effectiveness (69). POISE study data showed
that three-year OCA treatment reduced or stabilized hepatic
collagen deposition and ductular injury in PBC patients with
cirrhosis (69). The CombinationOCA and Statins forMonitoring
of Lipids (CONTROL) clinical trial study found increased
LDL in NASH patients treated with OCA (5, 10, or 25mg)
indicating altered lipid metabolism (73). The observed increase
in LDL cholesterol was reduced in NASH patients concurrently
treated with OCA and atorvastatin, a statin utilized to reduce
endogenous cholesterol production (73). The authors noted
that these two drugs were well-tolerated when utilized together,
addressing the observed increase in LDL cholesterol following
OCA treatment in NASH patients, but remained inconclusive
with respect to the combinatorial effect on hepatic injury (70,
73). Eaton et al. observed that decompensated patients with
cirrhotic PSC and PBC, OCA treatment led to the development
of jaundice and elevated liver enzyme levels (74). While the long-
term benefits of OCA are still being evaluated in various liver
diseases, it is still being explored as a potential.
During normal enterohepatic circulation, IBAT/ASBT is
responsible for the reabsorption of BAs in the intestinal tract
prior to secretion into the portal blood system (75). Additionally,
ASBT is responsible for cholehepatic shunting of BAs between
cholangiocytes and hepatocytes, which ultimately increases
hepatic BA pool. A common symptom of chronic cholestatic
liver disease is pruritus, intense itching of the dermis due
FIGURE 2 | Current bile acid receptor therapeutics and their effects in bile acid signaling. Briefly, Obeticholic acid (OCA) reduces bile acid (BA) synthesis, circulating
BA levels, and hepatic inflammation. This treatment may cause adverse effects such as pruritus and jaundice (in decompensated PBC patients). Ursodeoxycholic acid
(UDCA) alters BA pool and reduced hepatic inflammation and damage. In some cases, UDCA treatment has led to development of pruritus. Apical sodium bile acid
transporter (ASBT) inhibitors affect bile acid synthesis, circulation, secretion, and microbial composition in the intestine.
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to increased BA deposition (75). IBAT/ASBT inhibitors are
potential therapeutic candidates for this detrimental symptom
(76). Pilot studies conducted with various synthetic IBAT/ASBT
inhibitors have demonstrated variable results. The Al-Dury et al.
study reported patients who continued through A4250 (synthetic
IBAT/ASBT inhibitor) received relief from itching, but pruritus
returned during wash-out and BA sequestrant treatment. Despite
improvement of pruritus and lowered serum BAs, many patients
in the A4250 study dropped out early due to abdominal pain and
diarrhea (76). Similar benefits were identified in the pilot study
of GSK2330672 (synthetic IBAT/ASBT inhibitor), PBC patients
resulted with lowered serum BAs and increased serum FGF19.
The most common adverse events in this treatment cohort were
headaches and diarrhea, which provides reason to limit the
treatment length in patients with pruritus (77).
BA RECEPTOR AGONIST EFFECTS ON
THE GUT/LIVER AXIS DURING LIVER
DISEASE
BA species affect and regulate gut microbial species composition
(32). BA species and concentrations in different portions of
the gastrointestinal tract can result in increased side effects
including increased intestinal permeability and BA-induced
diarrhea (78). Elevated hydrophobic BAs in the colon are capable
of inducing inflammation which is reduced following CDCA
treatment alleviating the increased toxicity from insoluble BA
concentrations and mast cell secretory factors (i.e., histamine or
nerve growth factor NGF) (78, 79).
A small cohort of PBC patients exhibited altered gut
microbiome composition, compared to healthy controls,
which was partially reversed following 6-month UDCA
treatment (80). This study found eight-PBC associated
genera and a reduction in normal gut microbiome associated
microbial members including Faecalibacterium, Bacteroides,
Sutterella, and Oscillospira spp. A study from Selmi et al.
implicated increased N. aromaticivorans population is
responsible for the induction of PBC (81). Tang et al.
reported increased epithelial infiltration of Enterobacteriaceae
in PBC patients indicating increased permeability and
decreased gastrointestinal immune response in diseased
patients (80).
The gastrointestinal epithelial barrier plays an important role
in maintaining BA enterohepatic circulation homeostasis and
reduced inflammation from lipopolysaccharide (LPS) leakage.
BA circulation is necessary to avoid damaging increases
in colonic BAs that result in inflammation and intestinal
damage (78). Song et al. found that CDCA was capable of
reducing paracellular permeability and increased cell-to-cell tight
junctions via FXR activation inmice (82). Removal of commensal
gut microbiota in Mdr2−/− mice resulted in increased serum
liver enzyme levels, cholangiocyte senescence, and circulating
primary BAs (37). Alternatively, Li et al. discovered a depletion of
BA induced damage to the colon and reduced mast cell activation
and degranulation in FXR−/− mice or Z-guggulsterone treated
mast cells (79).
The role of the gut microbiome in BA homeostasis is still
being investigated. The disruption of the gut-liver axis can allow
infiltration of microbes, or their metabolic products, into the
enterohepatic circulation to prolong disease (83). Chronic liver
disease patients all maintain their own gut microbiome signature
that inherently play a role in disease development. Future studies
of BA-associated therapeutics should consider effects on the gut
microbiome and their metabolites in relation to changing BA
pool/circulation and chronic liver disease.
CONCLUSION
BA signaling, and therapeutics that alter them, have effects
on the gut microbiome and organs outside of the liver. The
use of BA receptor agonists and antagonists and their indirect
effects (BA pool, synthesis, circulation, and the gut microbiome
composition) is summarized in Figure 2. The human and mouse
gut microbiome fluctuates with the increase or decrease of
BAs, which can lead to increased inflammation and intestinal
malabsorption (19, 37, 80, 84–86). In depth exploration of
BA signaling and circulation during chronic liver diseases
may provide insight to disease amelioration or treatment
strategies. Understanding the role of the gut microbiome on
BA modification and circulation may allow for innovative
concurrent treatment for the reductions of inopportune side
effects of the currently investigated treatments, OCA and UDCA.
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